Nutromics appoints Kevin Plaxco CSO
Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Sep 07, 2026
The appointment strengthens Nutromics' scientific leadership as it advances toward regulatory clearance and commercial launch, potentially enhancing its credibility with investors and partners. However, as a private startup, the direct market impact is limited, though it may signal progress in the emerging continuous monitoring sector.
Nutromics, a Melbourne-based startup developing DNA-based wearable sensors for continuous molecular monitoring, announced the appointment of Professor Kevin W. Plaxco as Chief Scientific Officer (CSO). Plaxco, who invented the underlying electrochemical aptamer-based sensing technology, had previously served as an advisor and led the company's Biosensor Advisory Board. He succeeds Justin Gooding, who remains on the advisory board. The company is preparing to launch its first product in 2027 and plans to expand its platform to monitor additional drugs and biomarkers. Plaxco also commenced a role as Distinguished Professor at La Trobe University while remaining on leave from UC Santa Barbara.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard